Treatment Outcome of Gamma Knife Radiosurgery for GH-Secreting Pituitary Tumors

성장호르몬 분비 뇌하수체선종에 대한 감마나이프 방사선수술의 치료결과

  • Lim, Young Jin (Department of Neurosurgery, School of Medicine, Kyung Hee University) ;
  • Choi, Yeong Ho (Department of Neurosurgery, School of Medicine, Kyung Hee University) ;
  • Leem, Won (Department of Neurosurgery, School of Medicine, Kyung Hee University) ;
  • Lee, Ki Taek (Department of Neurosurgery, School of Medicine, Kyung Hee University) ;
  • Koh, Jun Seok (Department of Neurosurgery, School of Medicine, Kyung Hee University) ;
  • Kim, Tae Sung (Department of Neurosurgery, School of Medicine, Kyung Hee University) ;
  • Kim, Gook Ki (Department of Neurosurgery, School of Medicine, Kyung Hee University) ;
  • Rhee, Bong Arm (Department of Neurosurgery, School of Medicine, Kyung Hee University)
  • 임영진 (경희대학교 의과대학 신경외과학교실) ;
  • 최영호 (경희대학교 의과대학 신경외과학교실) ;
  • 임언 (경희대학교 의과대학 신경외과학교실) ;
  • 이기택 (경희대학교 의과대학 신경외과학교실) ;
  • 고준석 (경희대학교 의과대학 신경외과학교실) ;
  • 김태성 (경희대학교 의과대학 신경외과학교실) ;
  • 김국기 (경희대학교 의과대학 신경외과학교실) ;
  • 이봉암 (경희대학교 의과대학 신경외과학교실)
  • Received : 2000.10.13
  • Accepted : 2001.03.08
  • Published : 2001.05.28

Abstract

Objective : As for growth hormone(GH) secreting pituitary adenoma, it's remission should be declared on the basis of satisfactory controlling of the tumor, normalization of hormonal level, and symptomatic improvement of the patient. Several modalities of treatment have been applied and administered, and yet, this disease still remains as inveterate one to be fully treated. The purpose of this study is to evaluate the outcome of gamma knife radiosurgery(GKRS) for GH secreting pituitary adenoma, and to identify various factors affecting the outcome of the treatment. Method : A group of 24 out of 35 patients, treated by Leksell gamma knife unit during the period of March of 1992 through October of 1997, had been observed for more than two years. The mean target volume of microadenoma was $449.3mm^3(range 216-880mm^3)$, and that of macroadenoma was $3183.1mm^3(range 1456-13125mm^3)$. The tumor margin was covered with 50% isodose profile, and mean marginal dose was 25.2Gy(range 15-32.4Gy). The mean number of isocenter was 4.3(range 1-6). The exposed dose to the optic apparatus was less than 8Gy. The mean follow-up period was 37.8months(range 24-102months). Result : No patients showed any increase in the tumor volume during the follow-up period. And definite shrinkage of tumor volume(tumor volume reduction rate, TVRR : more than 50%) was obtained in 10 patients(41.7%). Twenty one patients(87.5%) had reduced hormonal level compared than pre-treatment level. Among them, normalization of the hormonal level was achieved in 12 patients(50%). Clinicoendocrinological remission was seen in 3 patients (12.5%). According to the results of statistical analysis, tumor volume(p=0.016),duration of symptoms(p=0.046), initial GH level(p=0.017), and the invasion of cavernous sinus(p=0.036) were significantly favorable to post-radiosurgical outcome. The TVRR was significantly related to post-radiosurgical reduction of serum GH level. Permanent complication was not seen. Conclusion : The authors concluded that GKRS is a safe and effective treatment modality for acromegaly. To otain the better outcome of GKRS in GH secreting pituitary adenoma, more careful and sophisticated treatment-planning is recommended.

Keywords